RE:RE:S&P Biotech ETF enters bull market up 29% in 13 trading days Poof, I think you ought to be just a little more circumspect and imaginative in your posts about Hunter syndrome and other Bioasis activities. You’re touting the smokescreen without considering what Bioasis’s real plans might be.
Although there is nothing inherently false in your posts, I think things are going to be much different than your rehashings of Bioasis’s very (VERY!!!), almost too carefully stated plans. You’re not parsing the meanings or exclusions in the Bioasis dialogues.
I can't pretend to know exactly how things are going to go, but I'm pretty sure that assessments of what Bioasis is and is NOT doing can be contemplated based on how DrDR presents them.
That Zoom webcast was a dance, a dance around full disclosures, and that means to me that there is truth in everything, but full meaning to almost nothing, with immense possibilities and plans not offered,.
I'm going to write about all this starting very soon but let's just say that buying a truly viable clinical-stage drug platform for 6.5 million 20-cent shares describes pretty much the current value of the Cresence package. The characterization of any upcoming CRES101/102 clinical trials as “proof-of-concept” gives Bioasis the wiggle room to later reveal, without disclosure consequences, that CRES101/102, etc. would never become commercially important drugs without xB3. I could be wrong about that my research does raise questions.
I will also be discussing why Bioasis is choosing to call itself The New Bioasis and why its business is now rare diseases. I will be discussing why DrDR revealed in the Zoom webcast that no xB3 drug can reach IND approval for 2 or 3 years, so much in contradiction to guidance given about xB3-001 back in 2019/20 when Bioasis made a pre-IND submission to the FDA that met with a favourable FDA response. Now, with 2 to 3 years to wait for any xB3 IND approvals, xB3-001 must actually have been 4 or 5 years away from such approval (or IND submission) at the time of the pre-IND submission. That is not to be taken lightly.
There’s a lot of good stuff going on, and I think everybody is going to make money, but it’s going to be different than most investors think. I think there may be limitations to xB3’s capabilities.
And I think that the Hunter Syndrome situation is exactly what Bioasis says it is, and maybe also what they’re not telling you it’s going to be. I made certain speculations about Hunter Syndrome two years ago. I will describe them again, soon, because I think they’re still possibilities.
Read more carefully, poof. You need to pay very careful attention to everything DrDR says, to what she doesn’t say, and to how she says everything.
jd